For the total GMP synthesis of complex carbohydrates and carbohydrate based medicinal chemistry, Dextra has a proven record of developing innovative solutions to minimise costs, reduce technology transfer issues and optimise robust route generation. Custom Synthesis—from mgs to multi kg scale, core capabilities include: Process development, glycosylation, hydrogenation and conjugation chemistry. Analytical Services—providing comprehensive analytical support for custom synthesis programs and independent analytical services GMP API Manufacturing—to support Phase I and Phase II clinical trials in reactors up to 50 L Dextra Catalogue—showcases a range of over 800 carbohydrate products, including neoglycoproteins, neoglycolipids, heparin derivatives, iminosugars, blood group products, oligosaccharides, glycans, building blocks and a range of rare sugars for glycobiology and reference standards. Dextra also has the ability to transfer complex chemical processes to its large scale manufacturing parent, New Zealand Pharmaceuticals. @DextraLabs
Looking for a particular Dextra Laboratories employee's phone or email?
The Dextra Laboratories annual revenue was $7.1 million in 2026.
Andy Hacking is the Research Director of Dextra Laboratories.
17 people are employed at Dextra Laboratories.
The NAICS codes for Dextra Laboratories are [325, 3254, 32541, 32].
The SIC codes for Dextra Laboratories are [283, 28].